Portola Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops therapeutics for acute and chronic cardiovascular and autoimmune/inflammatory diseases. The company's products include PRT054021, an oral factor Xa inhibitor for the prevention and treatment of deep vein thrombosis and pulmonary embolism after orthopedic surgery; for stroke prevention in patients with atrial fibrillation; and for secondary prevention of myocardial infarction and stroke. Its products also include PRT060128, an oral and intravenous ADP receptor antagonist for the treatment of patients with acute coronary syndrome; for the prevention of cardiovascular events in patients undergoing percutaneous coronary intervention; and for secondary prevention of myocardial infarction and stroke. In addition, the company's products include PRT062607, an oral Syk-specific kinase inhibitor for treating chronic inflammatory diseases and Rheumatoid Arthritis (RA) which is used to treat certain cancers including non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Portola Pharmaceuticals, Inc. was founded in 2003 and is based in South San Francisco, California.

In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. At Takeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer. They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.

Alexion Pharmaceuticals is a biopharmaceutical company, which is engaged in the discovery, development, and commercialization of biologic therapeutic products aimed at treating patients with severe and life-threatening disease states, including hematologic, kidney and neurologic diseases, transplant rejection, cancer, and autoimmune disorders. Its marketed product Soliris (eculizumab) is a therapy approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). In April 2009 and August 2009, the United States food and drug administration (FDA) and the European Commission (E.C.), respectively, granted Soliris orphan drug designation for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). In December 2009, its Rhode Island manufacturing facility received regulatory approval from the E.C. Or the production of Soliris.

Merck Sharp & Dohme Corp. engages in the research, development, and distribution of vaccines, prescription drugs, and animal health products. The company is headquartered in Whitehouse Station, NJ.

Mylan Laboratories Ltd. manufactures and supplies active pharmaceutical ingredients. The firm operates through two segments: Pharmaceuticals and Medical Supplies. It manufactures and supplies generic and branded generic formulations to various markets, including North America, Europe and Asia Pacific. Mylan Laboratories was founded on November 29, 1984 and is headquartered in Hyderabad, India.

Sichuan Haisco Pharmaceutical Co., Ltd., established on 2003-09-29, Business scope includes licensed projects:pharmaceutical production;Drug import and export;Pharmaceutical commissioned production;Drug retail(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Medical Research and Experimental Development;Specialty Chemicals Sales(Free of Hazardous Chemicals);Import and export;Technology Import and Export;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).

Sandoz AG, a subsidiary of Novartis AG, is a company headquartered in Basel, Switzerland, that develops generic medicines and biosimilars.

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services & Active Ingredients, Proprietary Products, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services & Active Ingredients segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research and development of differentiated formulations. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

Part of CSPC Pharmaceutical Group Ltd., CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co., Ltd. is a company headquartered in China. The firm engages in pharmaceutical research and development.

Tianjin Kelun Pharmaceutical Research Co., Ltd., established on 2014-08-01, Business scope includes general items:Medical Research and Experimental Development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).

Beijing Xinkaiyuan Pharmaceutical Technology Co., Ltd., established on 2014-03-20, Business scope includes biotechnology promotion;Medical Research;technology development;technical consulting;technology transfer;Import and export,Technology Import and Export,Agent import and export.(Enterprises independently choose operating projects according to law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policy of the district.)

Venturepharma, Inc. manufactures pharmaceutical products. It offers VP discovery, API development and outsourcing, biopharmaceuticals discovery, RX and OTC. The firm provides products for oncology, CNS, dermnova, diabetes, cardiovascular, respiration and vaccine. The company was founded in 1998 and is headquartered in Haidian, China.

Zhejiang Hongyuan Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of active pharmaceutical ingredient (API) of cardio-cerebral vascular drugs, intermediates, and other chemicals. Its products include intermediates of Atorvastatin Calcium, Rosuvastatin Calcium,\nPregabalin, Empagliflozin, Sotagliflozin, Teneligliptin, Betrixaban, Edoxaban, Sacubitril, Baricitinib, Lifitegrast, Roxadustat, Palbociclib, Ribociclib, Abemaciclib, Rucaparib, and Duloxetine. The company was founded on June 16, 2005 and is headquartered in Hangzhou, China.

Lunan Pharmaceutical Group is an Integrated pharmaceutical group, National innovative enterprise and National torch plan key high-tech enterprise that produces, researches and sells both traditional Chinese medicine, chemical medicine and bio-pharmaceutical medicinal products.

Anhui Healstar Pharmaceutical Co., Ltd. engages in production and sales of self-produced tablets, capsules, granules, small-volume injections, and raw materials. Its products include dipotassium phosphate, potassium dihydrogen phosphate, doxofylline, levofloxacin hydrochloride injection, doxofylline injection, compound potassium hydrogen phosphate injection, lysine calcium hydrogen phosphate granules, oral rehydration salt powder, dequinium chloride lozenges and potassium citrate granules. The company was founded on November 25, 2005 and is headquartered in Hefei, China.

Lunanbeite Pharmaceutical Co., Ltd., established on 2003-12-16, Business scope includes production,Sales:Western medicine,Chemical raw materials and preparations,Psychotropic drugs,Pharmaceutical Intermediates,Health products,food,medical instruments,cosmetic(Limited to production in industrial parks);drug research and development;Domestic Trade;Import and export of goods and technology;Sales of chemical products(Free of Hazardous Chemicals).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Jiangxi Synergy Pharmaceutical Co., Ltd. engages in the research and development, production and sale of chemical raw materials, active pharmaceutical ingredient and pharmaceutical intermediates. Its products includes anti-epileptic medicines, anti-ulcer medicines, anti-pyretic analgesics, non-steroid anti-inflammatory analgesics, anti-high blood pressure medicines and anti-depression drugs. The company was founded on April 20, 2004 and is headquartered in Yichun, China.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

With twin platform technologies, Interprotein provides highly active modulators for protein-protein interaction (PPI) targets. Their proprietary technology (INTENDD®) is built upon a different conceptual foundation from MD-based docking simulation methods, generating highly active compounds with unique scaffolds. On the other hand, their newly constructed libraries of helix-loop-helix peptide achieved a near 100% success rate in identifying strong binders with KD values in low nanomolar range.